Recent researches indicate that p62-NRF2 signaling activation induces tumorigenesis in precancerous cells and promotes the growth and therapy resistance of tumor cells in human hepatocellular carcinomas (HCC) [19,20], lung adenocarcinoma [20,21], and CRC [22]. This evidence concerns the gene SQSTM1 and hepatocellular carcinoma.